Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism

Rodrigo Carlini Fernando1, Diego Robles Mazzotti2, Hatylas Azevedo3, Alex Freire Sandes4, Edgar Gil Rizzatti5, Mariana Bleker de Oliveira5, Veruska Lia Fook Alves5, Angela Isabel Pereira Eugênio1, Fabricio de Carvalho1, Maria Aparecida Dalboni5, David Correa Martins6 & Gisele Wally Braga Colleoni1

A growing body of evidence suggests a key role of tumor microenvironment, especially for bone marrow mesenchymal stem cells (MSC), in the maintenance and progression of multiple myeloma (MM), through direct and indirect interactions with tumor plasma cells. Thus, this study aimed to investigate the gene expression and functional alterations of MSC from MM patients (MM-MSC) in comparison with their normal counterparts from normal donors (ND-MSC). Gene expression analysis (Affymetrix) was performed in MM-MSC and ND-MSC after in vitro expansion. To validate these findings, some genes were selected to be evaluated by quantitative real time PCR (RT-qPCR), and also functional in vitro analyses were performed. We demonstrated that MM-MSC have a distinct gene expression profile than ND-MSC, with 485 differentially expressed genes (DEG) - 280 upregulated and 205 downregulated. Bioinformatics analyses revealed that the main enriched functions among downregulated DEG were related to cell cycle progression, immune response activation and bone metabolism. Four genes were validated by qPCR - ZNF521 and SEMA3A, which are involved in bone metabolism, and HLA-DRA and CHIRL1, which are implicated in the activation of immune response. Taken together, our results suggest that MM-MSC have constitutive abnormalities that remain present even in the absence of tumors cells. The alterations found in cell cycle progression, immune system activation, and osteoblastogenesis suggest, respectively, that MM-MSC are permanently dependent of tumor cells, might contribute to immune evasion and play an essential role in bone lesions frequently found in MM patients.

Multiple myeloma (MM) is a hematologic malignancy of plasma cells, characterized by the infiltration of tumor cells in the bone marrow (BM), production of monoclonal (M) protein, which can be detected in the blood and/or urine of patients, and lesions in target-tissues and organs, including hypercalcemia, renal failure, anemia, and bone lesions1,2. In the United States, MM represents, approximately, 1% of all cancer types and 10% of hematologic malignancies2. The disease is often preceded by a pre-malignant condition known as monoclonal gammopathy

1Department of Experimental and Clinical Oncology, Discipline of Hematology and Hemotherapy, Federal University of São Paulo, UNIFESP, São Paulo, Brazil. 2Center for Sleep and Circadian Neurobiology, University of Pennsylvania, Pennsylvania, USA. 3Department of Pediatrics, Faculty of Medicine of the University of São Paulo, FMUSP, São Paulo, Brazil. 4Hematology, Fleury, Medicine and Health, São Paulo, Brazil. 5Department of Post-Graduation in Medicine, University Nine of July, UNINOVE, São Paulo, Brazil. 6Center of Mathematics, Computation and Cognition, Federal University of ABC, UFABC, Santo André, Brazil. Correspondence and requests for materials should be addressed to G.W.B.C. (email: gcolleoni@unifesp.br)
of undetermined significance (MGUS)\(^{24}\), which is present in, approximately, 3% of the population over 50 years and represents a risk of progression to MM of 1% per year\(^5\). Smoldering MM is another pre-malignant condition that can be classified between MGUS and MM, and presents a higher risk of progression to MM (approximately, 10% per year)\(^6\).

The overall survival of MM patients has improved considerably in recent years, both for patients eligible for autologous hematopoietic stem cell transplantation as well as for those ineligible for this therapeutic procedure\(^{7,8}\). However, these advances were not observed in all patients; for instance, among those classified as high-risk by molecular cytogenetic markers, the overall survival remains without significant advances\(^7\). In addition, most MM patients eventually relapse one or more times over the course of the disease, including those who have achieved a complete response, until the moment they might become refractory to all therapeutic arsenal available\(^6\).

The first breakthroughs in MM treatment were the introduction of melphalan in combination with prednisone, in the late 1960s\(^8\), and the introduction of high doses of chemotherapy followed by autologous hematopoietic stem cell transplantation for eligible patients, at the beginning of 1980s\(^9\). However, the greatest breakthrough occurred in 2000s, with the use of immunomodulatory agents, thalidomide\(^{11}\) and, subsequently, its analogues lenalidomide\(^{12,13}\) and pomalidomide\(^{14}\), as well as with the use of proteasome inhibitors, bortezomib\(^{15}\) and, more recently, carfilzomib\(^{16}\) and ixazomib\(^{17}\). Other therapeutic drugs have emerged, such as monoclonal antibodies daratumumab (anti-CD38)\(^{18}\) and elotuzumab (anti-SLAMF7)\(^{19}\), and histone deacetylase inhibitor panobinostat\(^{20}\).

Besides, there are a large number of new drugs with great anti-MM potential that are being tested in preclinical and clinical studies, and, likely, the therapeutic arsenal for MM treatment is going to become even greater in the coming years.

Despite the great advance in MM treatment aforementioned, which has improved patients’ overall survival, MM remains an incurable disease and, therefore, more information about its pathogenesis is essential for the search for new therapeutic targets. Genetic and epigenetic alterations are often found in tumor plasma cells, and accumulate over the course of the disease\(^21\). However, several of these alterations are already found in plasma cells of patients with MGUS, and smoldering MM. Thus, it is intuitive to think that, although such alterations are necessary for MM development, they are not sufficient\(^{21}\). In this scenario, the role of the tumor microenvironment for MM pathogenesis emerges.

A growing body of evidence suggests that tumor microenvironment plays a key role in the maintenance and progression of various cancers, including solid tumors\(^{22,23}\) and hematological malignancies\(^{24}\). In MM, the essential role of BM tumor microenvironment is well established and several studies have shown that plasma cells strongly depend on it\(^{25}\). Tumor plasma cells interact, directly and indirectly, with the tumor microenvironment, which is composed by cellular and noncellular elements, promoting proliferation, migration, survival, and drug resistance\(^{26–28}\). Among cellular elements, mesenchymal stem cells (MSC) deserve great attention in MM pathogenesis\(^{29}\). MSC is an adult stem cell, that can be found in different organs or tissues, especially in BM\(^{30}\). Apparently, MSC from MM patients (MM-MSC) do not share the same genetic alterations present in MM cells, ruling out the hypothesis of a common progenitor\(^{31}\). However, an increasing but still limited number of studies have demonstrated that MM-MSC might have some important differences compared to MSC from normal donors (ND-MSC), comprising from differences in gene and protein expression, to functional alterations, including lower proliferation and osteoblastic differentiation capacity, impaired immunomodulatory properties, among others\(^{31–35}\).

Therefore, the aim of this study was to explore the differences between MM-MSC and their normal counterparts, through gene expression and functional analyses, in order to add new insights to MM pathogenesis that could contribute to the development of new therapeutic molecules capable of disrupting the interaction between MM-MSC and MM cells, making these tumors cells more sensitive to drugs and immune response action.

**Casuistic and Methods**

**Ethical aspects.** This study was approved by the Institutional Review Board of the Federal University of São Paulo (CAAE: 34306314.6.0000.5505). BM samples were obtained after written informed consent of participants or legal representative, according to Helsinki Declaration and local regulations.

**Subjects and cell line.** Nineteen patients, from both genders, newly diagnosed with MM and without any previous treatment for the disease, i.e., no chemotherapy, no corticosteroids, no immunomodulators, no proteasome inhibitors, or bisphosphonates, were successfully enrolled in this study and allocated in the case group. The clinical laboratory characteristics of MM patients at the diagnosis are shown in Table 1. Seven BM normal donors for allogeneic stem cell transplantation, not matched by age or gender, were also included in the study and allocated in the control group. As an additional control, the HS-5 human bone marrow normal stromal cell line (ATCC, Manassas, VA, USA) was also used in some experiments.

**Isolation, expansion and characterization of MSC.** BM samples from normal donors (n = 7) and newly diagnosed MM patients (n = 19) were harvested from patients’ iliac crest. Then, BM mononuclear cells were isolated using Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, Bucks, GBR), according to the manufacturer’s instructions. Finally, MSC were sorted by Magnetic-Activated Cell Sorting (MACS) methodology, using CD105\(^+\) as a positive marker (Miltenyi Biotec, Bergisch Gladbach, DEU). MSC expansion was performed on αMEM with GlutaMAX and nucleoside medium\(^{36}\), supplemented with penicillin (100 U/mL)/streptomycin (100 μg/mL), fungizone (2.5 μg/mL) (All Gibco, Carlsbad, CA, USA) and 10% fetal bovine serum (FBS) (Vitrocell, Campinas, SP, BRA). MSC were incubated at 37°C, 5% CO\(_2\) and high humidity. During passage zero, the cells were fed twice a week, replacing only 50% of culture medium volume, until the cells reached 80% confluence or up to 21 days. Then, MSC were detached from the culture plastic with the aid of 0.25% trypsin-EDTA reagent (Gibco, Carlsbad, CA, USA), counted by tripan blue exclusion method and seeded again. From the first
passage onwards, 80% of the culture medium volume was replaced at the same conditions. After expansion, MM-MSC, ND-MSC and HS-5 cell line were immunophenotyped in the BD FACSCanto II flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Positive and negative markers were chosen based on the International Society for Cell Therapy Criteria37, using the following monoclonal antibodies: anti-CD105 PE, anti-CD90 FITC, and anti-CD73 PE-Cy 7, as positive markers, and anti-CD45 PE, anti-CD34 PerCP-Cy 5.5, anti-CD14 APC-H7, and anti-HLA-DR PB, as negative markers. Data were acquired in the software FACSDIVA, version 8.0.1 (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), and analyzed in the software Infinicyt, version 1.7 (Cytognos S. L., Salamanca, ESP).

The osteoblastic differentiation of MM-MSC (n = 4) and ND-MSC (n = 4) was performed in technical duplicates in 12-well microplates, using StemPro Osteogenesis Differentiation kit (Gibco, Carlsbad, CA, USA) and following the manufacturer’s instructions. Cells were fed twice a week, and on days 7, 14 and 21, the differentiation medium was removed and frozen at −80 °C for further analysis. In order to confirm the cell differentiation by a quantitative methodology, osteocalcin measurement was performed on the differentiation media collected from the cases and controls on days 7, 14 and 21, using the Human Osteocalcin Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions.

**Microarray hybridization and data acquisition.** For gene expression analysis, RNA samples were extracted from MM-MSC (n = 4) and ND-MSC (n = 4) using RNeasy Mini kit (Qiagen, Valencia, CA, USA). For each sample, three independent RNA extractions were performed. RNA quantification and purity analysis were performed on the NanoDrop® ND-8000 UV spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). In addition, RNA integrity was verified by 1% agarose gel electrophoresis, stained with ethidium bromide.

The microarray platform used was GeneChip® Human Exon 1.0 ST Array (Affymetrix, Santa Clara, CA, USA). On this platform, there are about 1.4 million probe sets, being approximately 4 probes per exon and 40 probes per gene. Microarray images were obtained using GeneChip Scanner 3000 7 G, and data were quantified using Affymetrix GeneChip Command Console® Software (both Affymetrix, Santa Clara, CA, USA), generating CEL files containing the raw data.

**Microarray data preprocessing and analysis.** Microarray raw data preprocessing and identification of differentially expressed genes (DEG) were performed using the AltAnalyze software www.altanalyze.org38. Once the analysis parameters were set, the raw data, in CEL format, was preprocessed by the Robust Multi-array Analysis (RMA) method39, which includes background correction, quantile normalization and summarization of the probes into specific probe sets. The probe sets were defined as differentially expressed between the groups when the p-values, corrected by the False Discovery Rate (FDR) method40, were less than 0.05 and the fold-changes (difference in expression in the case group versus control group) were greater than 1.5, in module. Differentially expressed probe sets were annotated for the purpose of identifying which genes they represent. To ensure that there was no great variability among within-condition samples, the coefficients of variation (CV), of the normalized gene expression values in log2, were calculated and, arbitrarily, the CV cut-off criteria less than 15% was established to consider a gene consistent. The microarray data, discussed in this article, have been deposited in NCBI’s Gene Expression Omnibus, and can be accessed through GEO Series accession number (ref GSE113736).

**Bioinformatics analyses workflow.** After identification of DEG, we performed the bioinformatics analyses in order to extract relevant biological information among these genes.

---

**Table 1.** Clinical and laboratorial characteristics of MM patients included in the study at diagnosis (N = 19).

| Characteristics          | Value     |
|--------------------------|-----------|
| Median age, years (range) | 67(43–80) |
| Sex, n (%)               |           |
| Male                     | 09 (47)   |
| Female                   | 10 (53)   |
| M-protein type, n (%)    |           |
| IgG                      | 08 (42)   |
| IgA                      | 07 (37)   |
| Light chain              | 04 (21)   |
| D&S stage, n (%)         |           |
| I                        | 01 (5)    |
| II                       | 02 (11)   |
| III                      | 16 (84)   |
| ISS stage, n (%)         |           |
| 1                        | 04 (21)   |
| 2                        | 04 (21)   |
| 3                        | 08 (42)   |
| NA                       | 03 (16)   |
Gene Co-Expression Network Analysis. Gene co-expression network construction and additional analyses were performed using Cytoscape 3.5.1 software, and three of its plug-ins. First, the GeneMANIA plug-in was used to generate the network, through the prediction of interactions among DEG, based exclusively on data published in the literature concerning co-expression. Then, another plug-in, CentiScaPe was used to calculate centrality measures of the genes (nodes) belonging to the constructed network. In our study, the calculated centrality measures were degree and betweenness, which represent, respectively, the number of connections of a node, i.e., the number of interactions of a gene with other genes in the network, and the number of shortest paths that pass through a node to connect other pairs of nodes. Lastly, GLay plug-in was used to find modules, also known as communities or clusters, which means groups of highly interconnected genes in the network.

Identification of high-hubs, hubs and bottlenecks. The calculated degree and betweenness values were used to construct a scatter plot, using GraphPad Prism 7.0 statistical software (GraphPad Software, San Diego, CA, USA). The scatter plot allows categorization of nodes in high hubs, hubs, and bottlenecks, as previously described by Azevedo et al. In summary, by dividing the plot into quadrants, the genes located in the upper right quadrant represent the high hubs (high degree and betweenness values), whereas the genes located in the lower right quadrant represent the hubs (genes with high degree and low betweenness values), and, finally, genes located in the upper left quadrant represent bottlenecks (genes with high betweenness and low degree values). The most relevant functions of the nodes with the highest degrees and/or betweenness values were manually searched using the GeneCards database.

Functional Enrichment Analysis. Overrepresented biological functions and pathways from GO databases, respectively, were searched in the subnetworks found, with the aid of Enrichr software and DAVID, version 6.8, software. P-value, adjusted for multiple comparisons by the FDR method, less than 0.05 was used as cut-off criteria to consider a category as significantly enriched.

Real-time RT-qPCR validation. In order to validate microarray results, total RNA extraction from MM-MSC (n = 13), ND-MSC (n = 5), and HS-5 cell line was performed using the RNA RNeasy Mini kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions. Then, cDNA was synthesized from 1.5 µg of total RNA, using SuperScript III and Oligo(dT) (both from Invitrogen, Carlsbad, CA, USA). Real time RT-qPCR was carried out using the 7500 Real Time PCR System, and the TaqMan Gene Expression Assays (both from Applied Biosystems, Foster City, CA, USA). All samples were evaluated in technical triplicates, and the Ct values for the endogenous control (GAPDH) and for the target genes (based on the bioinformatics analyses and their fold-change values), were determined during the log phase of the reaction. HS-5 cell line was used as a calibrator. For data analysis, the comparative ΔΔCt method was used, where ΔΔCt = Ct_targetgene – Ct_GAPDH and ΔΔCt = ΔCt_cases or controls – ΔCt_calibrator. The candidate genes were considered differentially expressed in MM-MSC when their expression levels showed at least a 2-fold increase or decrease in comparison to ND-MSC.

Telomere length measurement. Genomic DNA were extracted from MM-MSC (n = 19), ND-MSC (n = 7) and HS-5 cell line, using the QIAGEN DNA Mini kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions. After extraction, DNA quantification and purity analysis were performed in the DS-10 spectrophotometer (DeNovix, Wilmington, DE, USA). Then, all DNA samples were diluted to a final concentration of 50 ng/µL. MSC telomere length was determined by multiplex real time qPCR, as previously described by Cawthon, with minor modifications. In summary, this methodology consists in determining the relative ratio (T/S) between the telomere region copy number (T) and a single copy gene (S), using a relative standard curve. In our study, we chose the ALB gene as the single copy gene. T/S ratio for each sample is proportional to the mean telomere length. All experiments were performed in triplicate and our CV inter-assay was around 13.04%.

Cell cycle analysis. MM-MSC and ND-MSC frequencies distribution among cell cycle phases were evaluated in the BD FACSCanto II flow cytometer, using propidium iodide reagent (both Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The results were analyzed using ModFit LT software (Verity Software House, Topsham, ME, USA).

Statistical analyses. All statistical analyses were performed on IBM SPSS Statistics 20.0 software (IBM Corporation, Armonk, NY, USA), adopting α = 5% significance level. All graphs were plotted in GraphPad Prism 7 software (GraphPad Software, San Diego, CA, USA) and the results are shown as mean and standard deviation (SD). In order to evaluate the group effect (MM-MSC versus ND-MSC) over time (7, 14 and 21 days) on the measurements of the continuous variable osteocalcin, we used the Generalized Estimating Equation (GEE) with gamma distribution. Mann-Whitney U test was used to perform comparison among groups regarding relative gene expression by RT-qPCR. Additionally, to evaluate group effect on the continuous dependent variable mean telomere length (T/S), we used the independent t-test, as the probabilistic distribution of this variable was considered normal (p = 0.01, Kolmogorov-Smirnov test). We also assumed the homogeneous variance distribution between groups, since Levene’s test showed no significant difference between group variances (F = 0.053 and p = 0.819). Lastly, to investigate the existence of an association between the group (MM-MSC versus ND-MSC) and the relative frequency of cells in the different cell cycle phases (G0/G1, S and G2/M), we performed the Fisher’s exact two-tailed test, since some expected frequencies were less than five. Principal component (PCA) and t-distributed stochastic neighbor embedding (t-SNE) analyses were implemented in the R software in order to perform dimensionality reduction and assess how the samples group to each other.
the samples belonging to the same group (Figs S1 and S2). Analyses were able to separate the samples into the studied groups, showing a good degree of similarity between genes. Non-consistent genes between the groups. The majority of the non-consistent genes were non-protein coding RNAs, small nuclear RNAs, and small nucleolar RNAs. Arbitrarily, we considered that genes with the CV value less than 15%, i.e., with low variability within-condition, were consistent. Only 30 genes in the MM-MSC and 28 genes in the ND-MSC were considered not consistent out of the 485 DEG, with an overlap of 12 genes less than 15%, i.e., with low variability within-condition, were consistent. Only 30 genes in the MM-MSC and 28 genes in the ND-MSC were considered not consistent out of the 485 DEG, with an overlap of 12 non-consistent genes between the groups. The majority of the non-consistent genes were non-protein coding genes.

PCA and t-SNE analyses were performed to assess how the samples grouped to each other. Interestingly, both analyses were able to separate the samples into the studied groups, showing a good degree of similarity between the samples belonging to the same group (Figs S1 and S2). The first two PCA components (PC1 and PC2) were able to explain 23.4% and 11.9% of the data, respectively (Fig. S3).

Distinct gene expression profiling between MM-MSC and ND-MSC. After microarray data pre-processing and establishment of cut-off criteria (adjusted p-value < 0.05 and fold-change > 1.5), we found 485 DEG between MM-MSC and ND-MSC, including 280 upregulated and 205 downregulated genes. About 50% of them correspond to protein-coding genes, while the other half comprised genes encoding for long non-coding RNAs, small nuclear RNAs, and small nucleolar RNAs. Arbitrarily, we considered that genes with the CV values less than 15%, i.e., with low variability within-condition, were consistent. Only 30 genes in the MM-MSC group and 28 genes in the ND-MSC were considered not consistent out of the 485 DEG, with an overlap of 12 non-consistent genes between the groups. The majority of the non-consistent genes were non-protein coding genes.

The Cytoscape plug-in GeneMANIA was used to construct the network, using only interactions from the co-expression category. After filtering out the genes that were not connected in the network, we observed 195 genes (nodes) and 1515 interactions (edges) in the final network, with 31 genes upregulated, and 164 downregulated.

The degree and betweenness values of the 195 nodes were calculated, using the CenSiScaPe plug-in, and a scatter plot was built to visualize the relationship between degree (x-axis) and betweenness (y-axis) for each node. The plot was divided into four quadrants by applying an arbitrary cut-off of degree ≥ 29 and betweenness ≥ 671.5 (Fig. 2). The 20 DEG with the highest degree (hubs) values and the 20 DEGs with the highest betweenness (bottlenecks) values were highlighted (total of 36 downregulated genes). Among the hubs, half of them participate directly or indirectly in cell cycle progression. Additionally, some other genes are involved in functions related to the immune response, such as antigen processing and presentation via MHC class II, and regulation of the complement system activation (Table 2). In parallel, bottleneck genes participate in cell cycle regulation or immune response. Besides, some genes are involved in osteoblastogenesis (SEMA3A, BICC1, CHRLD1, and ZNF521) and HAS1 is involved in Waldenstrom's macroglobulinemia (Table 3), a post-follicular B-cell lymphoproliferative disorder also associated with M-protein production (IgM). Finally, three genes with high degree and betweenness (high hubs) are involved in cell cycle progression, while one high-hub participates in the regulation of complement system activation (Table 4). We also performed the identification of functional modules within the gene co-expression network, i.e., the localization of groups of highly connected nodes inside the original network (Fig. 3). Enrichment analysis of the functional modules was performed using the Enrichr and the DAVID softwares. Since the results obtained from both softwares were very similar, i.e., there was a great overlap between the terms of GO and the biological pathways of KEGG significantly enriched, we decided to show only the results generated by Enrichr. Overrepresented GO biological processes and KEGG pathways are represented in Figs 4 and 5 for module 1, and in Figs 6 and 7 for module 3. We did not find any biological processes nor biological.
Pathways significantly enriched in module 2. In module 1, enriched functions are mainly related to the immune response, T cell activation, antigen processing and presentation via MHC classes I and II, cytokine-mediated signaling pathways, and infectious and autoimmune diseases. In turn, enriched functions in module 3 are exclusively related to regulatory mechanisms of the cell cycle.

Real-time RT-qPCR validation. The microarray data were validated at the mRNA level by RT-qPCR for SEMA3A, ZNF521, HLA-DRA, CHI3L1, NEIL3, and GPC6. The genes HLA-DRA, CHI3L1, and ZNF521 were downregulated in 69%, 69% and 62% of MM-MSC, whereas genes SEMA3A, NEIL3 and GPC6 were downregulated in 54%, 38%, and 31% of MM-MSC, respectively (Fig. 8). Although all genes were downregulated in tumor samples when compared with normal controls, we only found a statistically significant difference for the ZNF521 gene (p = 0.046) (Fig. 9).

Multiple myeloma effects on MM-MSC telomere length. Telomere length comparison between MM-MSC and ND-MSC are showed in Fig. 10. As expected, MM-MSC presented lower telomeric length (mean = 0.97, SD = 0.11) than ND-MSC (mean = 1.04, SD = 0.11). However, the independent t test for the two samples showed that the difference found was not statistically significant (t(24) = 1.578, p = 0.128).

Cell cycle analysis showed no difference between MM-MSC and ND-MSC. The majority of MSC from cases and controls were in the quiescent phase (G0/G1 phase, MM-MSC: mean = 86.05%, SD = 8.97%, ND-MSC: mean = 85.82%, SD = 4.01%), with a few cells in S phase (MM-MSC: mean = 10.93%, SD = 7.74, ND-MSC: mean = 12.32%, SD = 2.87%), and in the G2/M phase (MM-MSC: mean = 3.02%, SD = 3.61%, ND-MSC: mean = 1.86%, SD = 1.33%) (Fig. 11). Fisher’s exact two-tailed test showed no statistically significant difference between the MM-MSC and ND-MSC percentages in the G0/G1, S and G2/M cell cycle phases (p = 1.00).

Discussion
Gene expression profiling analysis of MM-MSCs compared to ND-MSCs revealed 485 DEG, being 280 upregulated and 205 downregulated. When we built the co-expression network, there was a reversal and the downregulated genes became more represented in the network than the upregulated (164 versus 31), which was expected, since among the 280 upregulated genes, only 49 were protein-coding genes, whereas, of the 205 downregulated ones, 170 were protein-coding genes. Further exploration of DEG with different bioinformatics tools, showed that the most relevant enriched pathways and functions were among the downregulated genes, especially for those involved in cell cycle progression, immune response activation, and osteoblastic function and maturation. We have validated part of these findings through real-time quantitative PCR methodology, and additional in vitro functional assays. Six downregulated target genes, whose functions were mainly related to cell cycle progression, immune response activation, and osteoblastic function and maturation, were selected for validation at the mRNA level. Of the six target genes selected, a statistically significant difference was detected only for the ZNF521 (p = 0.048), which was downregulated in 62% of the MM-MSC evaluated samples, validating the microarray findings. In line with these results, a tendency to down expression was also observed for the HLA-DRA and CHI3L1 genes (both 69%), and for SEMA3A gene (54%). Regarding the functional in vitro assays, we chose to validate the cell cycle progression, since this function has already been reported by other authors as being impaired in MM-MSC, leading these cells to enter into an early cellular senescence process when compared...
The 16 DEG with the highest values of degree and low values of betweenness (hubs) in the gene co-expression network, and their most relevant functions. Keywords are underlined. aNA = Not Available.

| Gene       | Degree | Betweenness | Relevant function                                                                 | Reference       |
|------------|--------|-------------|-----------------------------------------------------------------------------------|-----------------|
| HLA-DRA    | 34     | 589.1       | Participates in immune response through presenting peptides derived from extracellular proteins to immune cells | GeneCards       |
| EXO1       | 34     | 515.9       | Exonuclease which is involved in DNA mismatch repair, and is required for somatic hypermutation and class switch recombination of immunoglobulin genes | GeneCards and UniProtKB |
| GMFG       | 33     | 667.5       | Serine/threonine-protein kinase which plays an important role in cell cycle regulation and carcinogenesis | —               |
| MELK       | 33     | 562.0       | Acts multiple times during the cell cycle, being required in nuclear movement prior to anaphase and chromosome segregation | UniProtKB       |
| FOXM1      | 32     | 335.3       | Transcriptional factor that regulates the expression of genes essential for cell cycle regulation | UniProtKB       |
| EVL2B      | 31     | 475.0       | Acts as a regulator of DNA replication and participates of checkpoints during cell cycle | —               |
| CDC20      | 31     | 426.8       | Participates in immune response, by helping CLIP removal from the peptide binding site of MHC class II molecules | Entrez Gene     |
| HLA-DMB    | 30     | 347.0       | Acts as a regulator of DNA replication and participates of checkpoints during cell cycle | Entrez Gene     |
| CDC6       | 30     | 302.5       | Kinase that plays a function as a cell cycle regulator, ensuring proper chromosome segregation before cell cycle progression | Entrez Gene     |
| BUB1B      | 29     | 435.7       | Promotes the organization of mitotic spindle microtubules around chromosomes | Entrez Gene     |
| IFI30      | 29     | 401.4       | Lyosomal thiol reductase involved in immune response, through MHC class II-restricted antigen processing | Entrez Gene     |
| HJURP      | 29     | 269.5       | Histone chaperone that promotes histone deposition, exchange and removal during nucleosome assembly and disassembly | Entrez Gene     |
| NCAPH      | 29     | 236.6       | Represents the regulatory subunit of the condensin complex, which is required for conversion of interphase chromatin into condensed chromosomes for mitosis progression | Entrez Gene and UniProtKB |
| NUSAP1     | 29     | 213.9       | Involved in cell cycle control, promoting transition through G1/S and G2/M and it is associated with cellular senescence pathway | Entrez Gene, GeneCards and UniProtKB |
| ASP1B      | 29     | 131.2       | Exonuclease which is involved in DNA mismatch repair, and is required for somatic hypermutation and class switch recombination of immunoglobulin genes | GeneCards       |
| CCNA2      | 29     | 99.5        | Involved in cell cycle regulator, ensuring proper chromosome segregation before cell cycle progression | Entrez Gene, GeneCards and UniProtKB |

Table 2. The 16 DEG with the highest values of degree and low values of betweenness (hubs) in the gene co-expression network, and their most relevant functions. Keywords are underlined. aNA = Not Available.

To perform the functional validation, we analyzed the cell cycle phases distribution, and the telomeric length quantification, through, respectively, flow cytometry, and multiplex real-time quantitative PCR methodologies. Regarding the cell cycle distribution, the majority of MM-MSC and ND-MSC were quiescent (G0/G1 (mean = 86.05%, SD = 8.97%)). The mean telomeric length was lower in MM-MSC in comparison with the ND-MSC (mean = 0.97, SD = 0.11 versus mean = 1.04, SD = 0.11). However, the difference found was not statistically significant, suggesting that the alterations in mRNA level related to the cell cycle are not related to a shortening of telomeres, or the casuistic was insufficient to detect this difference due to the biological variability among individuals.

Our results suggest that MM-MSCs have a distinct gene expression profiling in comparison with ND-MSCs. Interestingly, these cells showed hundreds of DEG even after in vitro expansion in the absence of tumor cells, confirming previous findings (Table 5). However, as discussed by André et al., the variability of the results found in these studies is relatively high, possibly due to several factors, including but not limited to: methodological differences prior to microarray execution - from the local and the form of MSC isolation, as well as its omERIC length quantification, through, respectively, flow cytometry, and multiplex real-time quantitative PCR. However, despite the differences, it is still possible to make relevant comparisons among these studies, and to raise quite pertinent hypotheses.

The first work to evaluate the overall gene expression profiling of MM-MSC, in comparison with ND-MSC, was published in 2007 by Corre et al. Among the 183 DEG/Probesets found, 59 were classified by the authors as belonging to the category of tumor microenvironment, comprising functions such as cellular communication, receptor signaling molecules, extracellular matrix, and secretory molecules. Additionally, they highlighted 40 genes (20 upregulated and 20 downregulated) as being essential for MM, of which four were also found in our study, one gene upregulated - ANGPTL4 - and three with diminished expression - NFR3, TNFRSF19, and FBLN1. The gene ANGPTL4 was also found downregulated in MM-MSC in three previous independent studies. More recent publications have demonstrated its multiple roles in osteolytic lesions, and MM bone disease, for example, through the promotion of osteoclast-mediated bone resorption, cartilage degradation, and angiogenesis. The NFR3 and FBLN1 genes, among other functions, participate in bone formation, i.e., the reduction of their expression can potentially contribute to the development of osteolytic lesions frequently found in patients with MM. Finally, the TNFRSF19 gene, a member of the TNF receptor superfamily, appears to mediate caspase-independent cell death (Gene database, NCBI).
In line with our results, André et al.33 also found enriched categories related to the cell cycle, such as, “M-phase”, “DNA replication”, “cell cycle regulation”, etc, among downregulated genes, like those results found by Wagner et al. (2008) in a study with ND-MSC in replicative senescence65. In our study, one of the functional modules detected through Cytoscape was composed mainly of genes involved in different pathways and biological processes related to cell cycle progression. In addition, André et al.33 also demonstrated that MM-MSCs have a lower proliferative rate, higher cell size, β-galactosidase increased activity, retention of cells in the S phase of the cell cycle, and secrete a senescence-associated molecule profile. Thus, the authors hypothesized that MM-MSCs appear to become senescent earlier than ND-MSCs. It is important to highlight that in this study, MSCs were expanded in vitro in monoculture, i.e. in the absence of other cells including MM plasma cells. Berenstein et al.64 demonstrated that MM-MSC, when cultured in the absence of tumor cells, accumulate in the S-phase of the cell cycle, increase β-galactosidase activity, and increase the expression of microRNAs associated with senescence. Moreover, they also demonstrated that MM-MSC co-cultivation with a MM cell line (KMS12-PE) is able to reverse, at least partially, the senescence phenotype of MM-MSC64. Contributing to these findings, the study of García-Gomez et al.34, which evaluated the gene expression profiling of MM-MSC expanded in monoculture and co-culture with the MM cell line MM.1S, observed that, after co-cultivation, some genes related to cell cycle progression become upregulated.

With regard to the other functional module identified through Cytoscape after performing functional enrichment analysis, we observed that the majority of the enriched categories was related to different aspects of the immune response, including antigen processing and presentation via MHC classes I and II, T cells activation, and immune response triggered by inflammatory cytokines. All genes belonging to these categories were downregulated in MM-MSC, suggesting that these biological pathways and processes could figure as a possible mechanism of immune escape. The immune system of MM patients is highly impaired81. A study published by our group

| Gene   | Degree | Betweenness | Relevant function                                                                 | Reference                  |
|--------|--------|-------------|-----------------------------------------------------------------------------------|----------------------------|
| EYA1   | 21     | 1098.0      | Acts as protein phosphatase and as transcriptional coactivator, participating in DNA double-strand break repair | GeneCards and UniProtKB    |
| DAPK1  | 25     | 1090.5      | Serine/Threonine kinase that participates in cell survival, apoptosis, and autophagy | GeneCards and UniProtKB    |
| GLT8D2 | 28     | 986.2       |                                                                                 | ENTREZ GENE                |
| PTN    | 24     | 876.9       | Secreted growth factor that plays essential roles in several pathways, including survival, cell migration, angiogenesis, and tumorigenesis | ENTREZ GENE                |
| SEMA3A | 19     | 842.6       | Positive regulator of osteoblastogenesis                                         | Hayashi et al.80          |
| BICC1  | 23     | 824.2       | Acts as a genetic determinant of osteoblastogenesis and bone mineral density      | Mesner et al.79           |
| SERPINB1|25     | 822.2       | Proteinase inhibitor that participates of innate immune response, being a potent intracellular inhibitor of granzyme H and regulating the activity of neutrophil proteases | ENTREZ GENE, UniProtKB    |
| CHRD1 | 25     | 809.0       | Antagonist of bone morphogenetic protein 4                                       | ENTREZ GENE                |
| ENPP2  | 27     | 796.0       | Phospholipase which is responsible for catalyzing the production of lysophosphatic acid in extracellular fluids, promoting cell proliferation and chemotaxis | ENTREZ GENE                |
| IL1R1  | 26     | 725.5       | Cytokine receptor, being an important mediator involved in immune response and inflammatory responses | ENTREZ GENE                |
| BAALC  | 14     | 722.2       | Indetified in patients with acute myeloid leukemia                               | ENTREZ GENE                |
| FOXO1  | 13     | 712.0       | Involved in cell cycle regulation and tumorigenesis                              | ENTREZ GENE                |
| MMD    | 24     | 707.0       | Molecule expressed by in vitro differentiated macrophage                         | ENTREZ GENE                |
| RAB27B | 13     | 703.3       | Belongs to the Rab protein family and plays a role in vesicular fusion and trafficking | ENTREZ GENE                |
| HAS1   | 23     | 694.4       | Enzyme that catalyzes the hyaluronan synthesis, a major component of most extracellular matrices. It is also associated with Waldenstrom, macroglobulinemia | ENTREZ GENE, GeneCards, and UniProtKB |
| ZNF521 | 19     | 671.5       | Zinc finger protein that promotes the maturation and function of mature osteoblasts | Hesse et al.73           |

Table 3. The 16 DEG with the highest values of betweenness and low values of degree (bottlenecks) in the gene co-expression network, and their most relevant functions. Keywords are underlined. *NA* = Not Available.

| Gene   | Degree | Betweenness | Relevant function                                                                 | Reference                  |
|--------|--------|-------------|-----------------------------------------------------------------------------------|----------------------------|
| NEIL3  | 42     | 2016.0      | Plays a role in cell cycle, by repairing telomere damage during phase S           | Zhou et al.50            |
| SERPINC1|45     | 1687.6      | Protein involved in the regulation of complement system activation               | ENTREZ GENE                |
| TPSYL5 | 31     | 1133.1      | Involved in modulation of cell growth, through TP53/p53 inhibition               | UniProtKB                 |
| APOBEC3B|29    | 805.4       | Might participate in cell growth and/or cell cycle control                         | ENTREZ GENE                |

Table 4. The 4 DEG with the highest values of degree and betweenness (high hubs) in the gene co-expression network, and their most relevant functions. Keywords are underlined.
showed that in BM of MM patients there is an increased expression of Treg cell markers, FOXP3 and CTLA4 genes, suggesting their accumulation in the BM microenvironment of MM patients, and a possible mechanism of tumor evasion from the immune system. Besides, other studies have showed that the decrease in the number of CD19+ B-cells, CD4+ and CD8+ T-cells in patients with MM is negatively correlated with survival in these individuals. Moreover, several studies have demonstrated a decrease in the number and/or function of different types of CD4+ and CD8+ T-cells in patients with MM. Another cell type affected in several types of cancer, including in MM, are dendritic cells, which mediate antigen-specific immune responses, through the antigen processing and presentation via MHC class II to T-cells. Magalhães et al. demonstrated that patients who achieved long-term control of MM have several differences in the immune system compared to patients with active disease, ranging from increased cytotoxic T cells and NK cells, to decreasing numbers of Treg cells, thus favoring the restoration of the antitumor cytotoxic responses of the immune system. The MSCs, under normal conditions, play an important immunoregulatory role. In the context of multiple myeloma, although they are not the tumor cells themselves, growing evidence from the literature has shown that their immunoregulatory functions are altered. A recent study by Chen et al., demonstrated in animal model that MM-MSCs promote the proliferation of tumor plasma cells through the inhibition of T-cell mediated immune responses via the PD-1 and PD-L1 pathway. Therefore, although no functional experiments have been performed to assess the immune...
Figure 5. Co-expression network enrichment analysis showing overrepresented KEGG pathways for the network nodes from module 1. KEGG = Kyoto Encyclopedia of Genes and Genomes.

Figure 6. Co-expression network enrichment analysis showing overrepresented GO-BP terms for the network nodes from module 3. GO-BP = Gene Ontology-Biological Process.
response in MM-MCS, based on literature evidence, genes related to different pathways of the immune system, including antigen processing and presentation, are expected to be altered in MM-MSC when compared to ND-MSC, as was observed in our study. However, the meaning of these alterations, as well as their role in the pathophysiology of the disease, still need to be elucidated.

Figure 7. Co-expression network enrichment analysis showing overrepresented KEGG pathways for the network nodes from module 3. KEGG = Kyoto Encyclopedia of Genes and Genomes.

Figure 8. Heat-map showing the expression pattern of the genes SEMA3A, GPC6, HLA-DRA, ZNF521, CHI3L1, and NEIL3, evaluated by RT-qPCR. The candidate genes were considered differentially expressed in MM-MSC when their expression levels showed at least a 2-fold increase or decrease in comparison to normal cells. MM-MSC = Multiple Myeloma Mesenchymal Stem Cells.
Regarding bone formation and resorption, the ZNF521 gene, which was downregulated in MM-MSCs, plays a key role in bone metabolism - this gene acts inhibiting the differentiation of osteoblast progenitors, through binding to RUNX2 pro-differentiation transcription factor, and simultaneously promoting maturation and correct function of mature osteoblasts. In agreement with these data, the RUNX2 gene was also downregulated in MM-MSC (FC = −1.65, gene expression evaluated only by microarray), possibly contributing to the imbalance of the bone metabolism observed in patients with MM. In addition, the downregulation of SEMA3A, which was classified as a bottleneck in the co-expression network, may also contribute to bone metabolism imbalance, since it plays an important role in osteoblastogenesis, inhibiting osteoclastic differentiation and stimulating osteoblastic differentiation. This gene also acts as an inhibitor of angiogenesis in endothelial cells, and a study reported that the loss of its inhibitory capacity may contribute to the transition from MGUS to the active form of MM. Finally,
the BICC1 gene, also downregulated in the MM-MSC and classified as a bottleneck, is a genetic determinant of osteoblastogenesis and mineral bone density.78.

The main limitation of our study is the small number of MM patients enrolled (n = 19). All of them were diagnosed in the same public hospital which receives most of MM new cases in stage III (84% in this study) and medical emergency, such as spinal cord compression, renal insufficiency, hypercalcemia or bone fractures, when immediate therapeutic interventions with corticosteroids and bisphosphonates are necessary, making patients ineligible for gene expression studies. Another limitation was that the controls were not age-matched to cases. In general, transplant normal donors were younger than MM patients. This situation could raise the hypothesis that the early senescence profile of MM-MSC, or the other differences detected through bioinformatics analysis, could be artificially created by the lack of age matching. Magalhães et al.79 conducted a meta-analysis of microarray studies that evaluated aging-related genes, and they identified 74 genes with higher levels of evidence. Of the 485 DEG in the MM-MSC compared to the ND-MSCs identified in this study, there was an overlap of only two genes within the 74 reported by Magalhães et al.79. The genes were SERPING1 and S100A6, which are involved with the regulation of complement cascade and cell cycle progression and differentiation, respectively. Thus, the absence of age-matched cases and controls probably did not significantly affect our data. Additionally, MSC from both groups were expanded in vitro, which might introduce artifacts. However, unfortunately, MSC from normal donors and patients with MM are found in very low number in the BM. Therefore, in order to obtain the appropriate number of cells to perform experiments, these cells must be expanded in vitro previously. Finally, MM-MSCs were expanded in vitro in the absence of MM tumor cells. However, despite this limitation, the comparisons among different studies, including those that were carried out in co-culture, allow the researchers to

Figure 10. Mean telomere length of MM-MSC (n = 19) in comparison with ND-MSC (n = 7), expressed by T/S ratios. The experiments were performed in technical triplicates and the results are presented as mean and standard deviation (SD). To determine the effect of group on MSC telomere length, the independent t-test was used. NS = Not Significant; MM-MSC = Multiple Myeloma-Mesenchymal Stem Cells; ND-MSC = Normal Donor-Mesenchymal Stem Cells.

Figure 11. Cell cycle analysis of MM-MSC (n = 17) in comparison with ND-MSC (n = 7), expressed by cell percentages over G0/G1, S and G2/M phases. The results are presented as mean and standard deviation (SD). To evaluate the association of the group and the MSC frequencies over cell cycle phases, the Fisher’s exact two-tailed test was used. NS = Not Significant; MM-MSC = Multiple Myeloma-Mesenchymal Stem Cells; ND-MSC = Normal Donor-Mesenchymal Stem Cells.
generate quite interesting hypotheses, which can be tested through comparisons between the monoculture and the co-culture of the MM-MSC with or without MM cells.

In summary, our study demonstrated that MM-MSCs have a distinct gene expression profile when compared to the ND-MSCs, corroborating previous studies. The functional enrichment analysis of the gene co-expression network revealed that the main deregulated functions in MM-MSC are related to cell cycle progression, activation of the immune response, and to bone metabolism, which may contribute directly or indirectly to MM pathophysiology. Due to the essential role of these cells in the maintenance and progression of MM, potential therapeutic targets and new drugs capable of disrupting the interactions between MM-MSC and MM cells are welcome.

Table 5. Microarray studies addressing gene expression profiling of MM-MSC compared to ND-MSC.

| Comparison design | Microarray platform | Number of DEG\(^{+}\)/Probesets |
|-------------------|---------------------|-------------------------------|
| MM-MSC\(^{+}\) vs. ND-MSC\(^{+}\) | GeneChip Human Genome U133 Plus 2.0 Array | 183 |
| MM-MSC vs. ND-MSC | GeneChip Human Genome U133A Array | 79 |
| MM-MSC vs. ND-MSC | GeneChip Human Genome U133 Plus 2.0 Array | 646 |
| MM-MSC vs. ND-MSC | GeneChip Human Genome U133 Plus 2.0 Array | 2583 |
| MM-MSC vs. ND-MSC | GeneChip Human Genome U133 Plus 2.0 Array | 2553 |
| MM-MSC vs. ND-MSC | GeneChip Human Exon 1.0 ST Array | 485 |

References

1. Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351(18), 1860–73 (2004).
2. Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364(11), 1046–60 (2011).
3. Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 113(22), 5412–7 (2009).
4. Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 113(22), 5418–22 (2009).
5. Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354(13), 1362–9 (2006).
6. Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356(25), 2582–90 (2007).
7. Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 111(5), 2516–20 (2008).
8. Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 28(5), 1122–8 (2014).
9. Alexanian, R. et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. Jama. 208(9), 1680–5 (1969).
10. McElwain, T. J. & Powles, R. L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 2(8354), 822–4 (1983).
11. Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565–71 (1999).
12. Rajkumar, S. V. et al. Combination therapy with lenalidomide plus dexamethasone (RevDex) for newly diagnosed myeloma. Blood. 106(13), 4050–3 (2005).
13. Richardson, P. G. et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 108(10), 3458–64 (2006).
14. Lacy, M. et al. Pomalidomide (CC4017) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008–14 (2009).
15. Orlowski, R. Z. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20(22), 4420–7 (2002).
16. Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372(2), 142–52 (2015).
17. Richardson, P. G. et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 124(7), 1038–46 (2014).
18. Lohkhorst, H. M. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373(13), 1207–19 (2015).
19. Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373(7), 621–31 (2015).
20. Cheng, T., Grasse, L., Shah, J. & Chandra, J. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma. Drug Today (Barc). 51(8), 491–504 (2015).
21. Bianchi, G. & Munshi, N. C. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 125(20), 3049–58 (2015).
22. Chung, H. W. & Lim, J.-B. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J. Gastroenterol. 20(7), 1667–80 (2014).
23. Villanueva, J. & Herlyn, M. Melanoma and the tumor microenvironment. Curr. Oncol. Rep. 10(5), 439–46 (2008).
24. Zhou, J., Maurerer, K., Farina, L. & Gribben, J. G. The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci. 10, 1581–96 (2005).
25. Mitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Richardson, P. G. & Anderson, K. C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer. 42, 1564–73 (2006).
26. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G. & Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 7(8), 585–98 (2007).
27. Poda, K., Richardson, P. G., Hideshima, T., Chauhan, D. & Anderson, K. C. The malignant clone and the bone-marrow environment. Best Pract. Res. Clin. Haematol. 20(4), 597–612 (2007).
28. Caes, J., Van Valkenborgh, E., Menu, E., Van Camp, B. & Vanderkerken, K. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer. 95(3), 301–13 (2008).
29. Reagin, M. R. & Ghobrial, I. M. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin. Cancer Res. 18(2), 342–9 (2012).
30. Bianco, P., Robey, P. G. & Simmons, P. J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2(4), 313–9 (2008).
31. Arnulf, B. et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 21(1), 158–63 (2007).
32. Corre, J. et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 21(5), 1079–88 (2007).
33. Andre, T. et al. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One. 8(3), e59756 (2013).
34. Garcia-Gomez, A. et al. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma: implications in myeloma progression and myeloma bone disease. Oncotarget. 5(18), 8284–305 (2014).
35. Garayoa, M. et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia. 23(6), 1515–27 (2009).
36. Sotropoulou, P. A., Perez, S. A., Salsigianni, M., Baveyanis, C. N. & Papamichail, M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells. 24(2), 462–71 (2006).
37. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 8(4), 315–7 (2006).
38. Emig D. et al. AIAnalyzer and DomainGraph: analyzing and visualizing exon expression data. Nucleic Acids Res. 38(Web Server issue), W755–62 (2010).
39. Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31(4), e15 (2003).
40. Benjamin, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological). 57(1), 289–300 (1995).
41. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498–504 (2003).
42. Warde-Farley D. et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting function. Nucleic Acids Res. 38 (Web Server issue), W214–20 (2010).
43. Soci, G., Kuchinsky, A., Morris, J. H., States, D. I. & Meng, F. GLay: community structure analysis of biological networks. Bioinformatics. 26(24), 3135–7 (2010).
44. Azevedo, H. et al. Intragraft transcriptional profiling of renal transplant patients with tubular dysfunction reveals mechanisms underlying graft injury and recovery. Hum Genomics. 10, 2 (2016).
45. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25(1), 25–9 (2000).
46. Gene Ontology Consortium: going forward. Nucleic Acids Res. 43(Database issue), D1049–56 (2015).
47. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27–30 (2000).
48. Kanehisa M. et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42(Database issue), D199–205 (2014).
49. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference source for gene and protein annotation. Nucleic Acids Res. 44(D1), D457–62 (2016).
50. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45(D1), D353–61 (2017).
51. Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 14, 128 (2013).
52. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44(W1), W90–7 (2016).
53. Huang, D. W. Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics resources. Nature Protoc. 4(1), 44–57 (2009).
54. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta T) Method. Methods. 25(4), 402–8 (2001).
55. Cawthon, R. M. Telomere measurement by quantitative PCR. Nucleic Acids Research. 29(4), 402–8 (2001).
56. Cawthon, R. M. Telomere measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Research. 44(D1), D457–62 (2016).
57. Cawthon, R. M. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Research. 37(3), e21–e (2009).
58. Kuchen, K. et al. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma disease. Exp. Hematol. 38(2), 141–53 (2010).
59. Knowles, H. J. Multiple roles of angiopeptin-like 4 in osteolytic disease. Frontiers in Endocrinology. 8, 80 (2017).
60. Dotterweich, J. et al. Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -implications for myeloma bone disease. Bone. 93, 155–66 (2016).
61. Hang Pham, L. B. et al. Investigating the effect of fibulin-1 on the differentiation of human fetal inferior turbinate-derived mesenchymal stem cells into osteoblasts. J. Biomed. Mater. Res. A. 105(8), 2291–2298 (2017).
62. Cooley, M. A. et al. Fibulin-1 is required for bone formation and BMP-2-mediated induction of Osterix. Bone. 69, 30–8 (2014).
63. Wanner, W. et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One. 3(5), e2213 (2008).
64. Berenstain, R. et al. Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region. BMC Cancer. 15, 68 (2015).
65. Pratt, G., Goodyear, O. & Moss, P. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138(5), 563–79 (2007).
66. Braga, W. M. T. et al. FOXO3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells. Cancer Immunology, Immunotherapy. 63(11), 1189–97 (2014).
67. Kay, N. E. et al. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood. 90(1), 340–5 (1997).
68. Kay, N. E. et al. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br. J. Haematol. 100(3), 459–63 (1998).
69. Kay, N. E. et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood. 98(1), 23–8 (2001).
70. Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. Journal of Hematology & Oncology. 9, 116 (2016).
71. Brown, R. D. et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. *Blood.* **98**(10), 2992–8 (2001).
72. Brimnes, M. K., Svane, I. M. & Johnsen, H. E. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. *Clin. Exp. Immunol.* **144**(1), 76–84 (2006).
73. Pequeno de Magalhães, R. J. et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. *Haematologica.* **98**(1), 79–86 (2013).
74. Chen, D. et al. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway. *Cell Cycle.* **17**(7), 858–87 (2018).
75. Hesse, E. et al. Zinc finger protein 521, a new player in bone formation. *Ann N Y Acad Sci.* **1192**, 32–7 (2010).
76. Negishi-Koga, T. & Takayanagi, H. Bone cell communication factors and Semaphorins. *Bonekey Rep.* **1**, 183 (2012).
77. Vacca, A. et al. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. *Blood.* **108**(5), 1661–7 (2006).
78. Mesner, L. D. et al. Bicc1 is a genetic determinant of osteoblastogenesis and bone mineral density. *J. Clin. Invest.* **124**(6), 2736–49 (2014).
79. de Magalhães, J. P., Curado, J. & Church, G. M. Meta-analysis of age-related gene expression profiles identifies common signatures of aging. *Bioinformatics.* **25**, 875–81 (2009).
80. Hayashi, M. et al. Osteoprotection by semaphorin 3A. *Nature.* **485**(7396), 69–74 (2012).
81. Zhou, J. et al. NEIL3 Repairs Telomere Damage during S Phase to Secure Chromosome Segregation at Mitosis. *Cell Rep.* **20**(9), 2044–56 (2017).

Acknowledgements

The authors thank all the professionals who provided essential technical support during the conduction of this work. This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP (grant number 2010-17668-6). R.C.F. was partially supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq (grant number 167484/2014-1).

Author Contributions

Rodrigo Fernando: Study design, data collection, analysis and interpretation, and manuscript writing. Diego Mazzotti: Bioinformatics analysis, significant intellectual insights, and review and approval of the final version of the article. Hatylas Azevedo: Bioinformatics analysis, significant intellectual insights, and review and approval of the final version of the article. Alex Sandes: Flow cytometry data acquisition, analysis and interpretation, and review and approval of the final version of the article. Edgar Rizzatti: Flow cytometry data acquisition, analysis and interpretation, and review and approval of the final version of the article. Mariana de Oliveira: Significant intellectual insights, and review and approval of the final version of the article. Angela Eugênio: Significant intellectual insights, and review and approval of the final version of the article. Maria Dalboni: ELISA data acquisition, analysis and interpretation, significant intellectual insights, and review and approval of the final version of the article. Fabricio de Carvalho: Study design, data collection, and review and approval of the final version of the article. David Martins: Bioinformatics analysis, significant intellectual insights, and review and approval of the final version of the article. Gisele Colleoni: Study design, data analysis and interpretation, and manuscript writing.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-38314-8.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019